search
Back to results

Renal and Hormonal Effects of Pioglitazone

Primary Purpose

Diabetes, Hypertension

Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
Pioglitazone
Metformin
Sponsored by
University Hospital, Geneva
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes focused on measuring diabetes, blood pressure, pioglitazone, sodium, insulin resistance, renal function, sodium, pioglitazone

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type II Diabetes
  • Hypertension

Exclusion Criteria:

  • Cardiac or renal diseases
  • Anaemia
  • Drugs like aspirin, non steroidal anti-inflammatory drugs and hormonal replacement therapy.

Sites / Locations

  • Pechère-Bertschi Antoinette

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Placebo Comparator

Arm Label

Pioglitazone

Metformine

Arm Description

placebo-controlled, randomized, cross-over study

placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance

Outcomes

Primary Outcome Measures

Effects of Pioglitazone on Renal Hemodynamics
At the end of each treatment diet phase, renal clearances were performed for the determination of GFR and RBF
Effects of Pioglitazone on Sodium and Lithium Clearances
At the end of each treatment and diet phase, 24 urine collections were collected for the determination of sodium and lithium clearances
Effects of Pioglitazone on 24h Blood Pressure Control
24 hour blood pressure measurements were performed after each treatment/diet phase

Secondary Outcome Measures

Effects of Pioglitazone on Salt Sensitivity

Full Information

First Posted
March 19, 2010
Last Updated
March 24, 2010
Sponsor
University Hospital, Geneva
Collaborators
University of Lausanne Hospitals
search

1. Study Identification

Unique Protocol Identification Number
NCT01090752
Brief Title
Renal and Hormonal Effects of Pioglitazone
Official Title
Effects of the PPAR-gamma Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Diabetic and Hypertensive Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
January 2009
Overall Recruitment Status
Completed
Study Start Date
October 2005 (undefined)
Primary Completion Date
October 2007 (Actual)
Study Completion Date
October 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University Hospital, Geneva
Collaborators
University of Lausanne Hospitals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study examines the effects of pioglitazone on renal sodium handling in subjects prone to insulin resistance, i.e. diabetic and/or hypertensive subjects.
Detailed Description
Aim: Glitazones are powerful insulin sensitizers prescribed for the treatment of type 2 diabetes. Their use is however associated with fluid retention and an increased risk of congestive heart failure. We previously demonstrated that pioglitazone increases proximal sodium reabsorption in healthy volunteers. This study examines the effects of pioglitazone on renal sodium handling in subjects prone to insulin resistance, i.e. diabetic and/or hypertensive subjects. Methods: In this double-blind, randomized, placebo-controlled, four-way, cross-over study, we examined the effects of pioglitazone (45mg daily during 6 weeks) or placebo on renal, systemic and hormonal responses to changes in sodium intake in 16 individuals, 8 with type 2 diabetic and 8 with hypertension.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Hypertension
Keywords
diabetes, blood pressure, pioglitazone, sodium, insulin resistance, renal function, sodium, pioglitazone

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pioglitazone
Arm Type
Placebo Comparator
Arm Description
placebo-controlled, randomized, cross-over study
Arm Title
Metformine
Arm Type
Placebo Comparator
Arm Description
placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
Intervention Type
Drug
Intervention Name(s)
Pioglitazone
Other Intervention Name(s)
Actos
Intervention Description
placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
Glucophage, Glumetza, Fortamet, Riomet
Intervention Description
placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
Primary Outcome Measure Information:
Title
Effects of Pioglitazone on Renal Hemodynamics
Description
At the end of each treatment diet phase, renal clearances were performed for the determination of GFR and RBF
Time Frame
2008
Title
Effects of Pioglitazone on Sodium and Lithium Clearances
Description
At the end of each treatment and diet phase, 24 urine collections were collected for the determination of sodium and lithium clearances
Time Frame
2007
Title
Effects of Pioglitazone on 24h Blood Pressure Control
Description
24 hour blood pressure measurements were performed after each treatment/diet phase
Time Frame
march 2009
Secondary Outcome Measure Information:
Title
Effects of Pioglitazone on Salt Sensitivity
Time Frame
2009

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type II Diabetes Hypertension Exclusion Criteria: Cardiac or renal diseases Anaemia Drugs like aspirin, non steroidal anti-inflammatory drugs and hormonal replacement therapy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antoinette Pechere-Bertschi, MD
Organizational Affiliation
University Hospital, Geneva
Official's Role
Study Director
Facility Information:
Facility Name
Pechère-Bertschi Antoinette
City
Geneva
ZIP/Postal Code
1211
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
21752899
Citation
Zanchi A, Pechere-Bertschi A, Burnier M, Bonny O. Effects of pioglitazone on renal calcium excretion. J Clin Endocrinol Metab. 2011 Sep;96(9):E1482-5. doi: 10.1210/jc.2011-0373. Epub 2011 Jul 13.
Results Reference
derived
PubMed Identifier
20414637
Citation
Zanchi A, Maillard M, Jornayvaz FR, Vinciguerra M, Deleaval P, Nussberger J, Burnier M, Pechere-Bertschi A. Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. Diabetologia. 2010 Aug;53(8):1568-75. doi: 10.1007/s00125-010-1756-2. Epub 2010 Apr 23.
Results Reference
derived

Learn more about this trial

Renal and Hormonal Effects of Pioglitazone

We'll reach out to this number within 24 hrs